Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
6 evidence topics · 7 sources
Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years
“Majority of patients have a mild-moderate course, most active at diagnosis and then in varying periods of remission or mild activity; about 10–15% patients experience an aggressive course, and the cumulative risk of relapse is 70–80% at 10 years. Almost 50% patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ~50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 10y follow-up study of the IBSEN cohort, four different profiles of disease activity were reported by patients: remission or mild severity after initial period of high activity (55%), chronic intermittent symptoms (37%), chronic continuous symptoms (6%) and increase activity after period of low activity (1%) (18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease extent at diagnosis and proximal extension
“At diagnosis, the majority of patients had left-sided colitis (median 40.1%; IQR, 32.6–44.6); 30.5% (29.8–32.6) and 29.4% (25.3–34.7) were diagnosed with extensive colitis and proctitis, respectively (9–17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall rates of progression ranged from 12–30%, with cumulative 5-year risk of progression being approximately 13% (10,13,14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and colectomy: contemporary US inception cohort
“Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y risk of colectomy was 2.2% (95% CI, 1.8–2.7) and 5.7% (95% CI, 4.8–6.7), respectively (Table 2). Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colectomy: meta-analysis of population-based cohorts
“In patients with UC (26 studies), overall 1-, 5-, and 10-year risk of colectomy was 4.0% (95% CI,3.3–5.0), 8.8% (7.7–10.0) and 13.3% (11.3–15.5), respectively, with decline in risk over time (p<0.001). Corresponding contemporary risks were 2.8% (2.0–3.9), 7.0% (5.7–8.6) and 9.6% (6.3–14.2), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Life expectancy: about 5 years shorter than people without ulcerative colitis
Mortality: all-cause and cause-specific standardized mortality ratios
“The all-cause mortality summary SMR for inception cohort and population cohort UC studies was 1.19 (95% confidence interval, 1.06–1.35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease was increased, whereas mortality from cardiovascular disease was decreased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UC has not been associated with an increased mortality, as compared to the general population, except in one cohort (23, 57–62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A meta-analysis of both administrative and inception population-based studies recently observed a pooled mortality rate of respectively 0.7% and 5.3% for elective and emergent surgery, respectively without significant decrease over time (39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote